Bradley C. Leibovich, M.D.

Location

SUMMARY

Bradley C. Leibovich, M.D., studies the diagnosis, pathogenesis, treatment and prognostic factors of urologic malignancies. Research focus areas include the molecular biology, biomarkers and immunological factors in disease progression in cell carcinoma. His work also includes using artificial intelligence (AI) in urology and healthcare delivery. This use of AI to design digital tools improves healthcare delivery and disease prediction and prevention. His work on prediction of renal cell carcinoma prognosis includes the "Leibovich Score," a tool used internationally. He serves as the medical director of the Mayo Clinic Center for Digital Health.

Focus areas

• Renal cell carcinoma biomarkers. Dr. Leibovich's work led to the discovery and development of immune-based predictors of prognosis as well as the development of currently used FDA-approved systemic checkpoint blockade treatments.
• Development of algorithms in renal cell carcinoma. These algorithms are used to predict prognosis and make therapeutic decisions.
• Data acquisition in urologic cancer. Dr. Leibovich's data acquisition and analysis approaches improve surgical and nonsurgical care for people with urologic cancers.
• Machine learning approaches to renal tumors. Machine learning approaches to segmentation of renal tumors using CT scans were developed and are now in clinical use. Ongoing radiomic work develops a "radiologic biopsy" including histologic features and predictions of disease biology.
• Remote data acquisition. Dr. Leibovich studies remote data acquisition for disease prediction, prevention and interception.
• Digital care delivery. Digital care delivery, platforms, decision support, and AI-enabled data presentation and insights are areas of research.

Significance to patient care

Dr. Leibovich's research and clinical interests have been focused on renal cancer for the majority of his career. He researches determinants of renal cancer prognosis and the immune and cellular biology of renal cancer. Dr. Leibovich's identification of genomic and proteomic factors of importance in renal cancer have had many direct benefits in improving outcomes in people's care. Using the power of large datasets and advanced analytic means now available, Dr. Leibovich is finding new ways to predict, diagnose, cure and ultimately prevent disease as well as increase equitable access to high-quality care.

Professional highlights

• Society of Urologic Oncology:
  • Education chair, 2023-present.
  • Member, board of directors, Clinical Trials Consortium, 2020-present.
• Kidney Cancer Association:
  • Chair, board of directors, 2021-present.
  • Andrew C. Novick Award, 2014.
• Medical director, Center for Digital Health, Mayo Clinic, 2020-present.
• Team Science Award, Mayo Clinic, 2023.
• Chair, Department of Urology, Mayo Clinic, 2013-2021.
• David C. Utz, M.D., Professor of Urology, Mayo Clinic, 2015.